Present status and perspectives in functional analysis of p53 in chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 53, Issue 8, 2012, Pages 1445-1451

  De Viron, Emeline ^a   Michaux, Lucienne ^b,c   Put, Natalie ^b   Bontemps, Françoise ^a   Van Den Neste, Eric ^a,c  

^a DE DUVE INSTITUTE   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

acute myeloid leukemia; cytarabine; FLT3 inhibitor; Linifanib

Indexed keywords

ANTINEOPLASTIC AGENT; ATM PROTEIN; MICRORNA 34A; PROTEIN P53;

ATM PROTEIN GENE; CANCER PROGNOSIS; CHEMOSENSITIVITY; CHRONIC LYMPHATIC LEUKEMIA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENE STRUCTURE; GENE TARGETING; GENETIC ANALYSIS; HUMAN; PRIORITY JOURNAL; PROTEIN P53 GENE; REVIEW; TUMOR GENE;

CYTOGENETICS; DNA DAMAGE; GENE DELETION; GENE EXPRESSION REGULATION, LEUKEMIC; GENES, P53; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICRORNAS; PHENOTYPE; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84864244657     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.660630     Document Type: Review

References (103)

1. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352:804-815.
2. Dighiero G, Hamblin TJ. Chronic lymphocytic leukaemia. Lancet 2008;371:1017-1029.
3. Gribben JG, O'Brien S. Update on therapy of chronic lymphocytic leukemia. J Clin Oncol 2011;29:544-550.
4. Hallek M, Pfl ug N. State of the art treatment of chronic lymphocyticleukaemia. Blood Rev 2011;25:1-9.
5. Rao VA, Plunkett W. Activation of a p53-mediated apoptotic pathway in quiescent lymphocytes after the inhibition of DNA repair by fl udarabine. Clin Cancer Res 2003;9:3204-3212.
6. Rosenwald A, Chuang EY, Davis RE, et al. Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. Blood 2004;104:1428-1434.
7. Gandhi V. p53 as a predictor for chemotherapy response in CLLcells. Leuk Lymphoma 2007;48:219-220.
8. Zenz T, Benner A, Dohner H, et al. Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathway. Cell Cycle 2008;7:3810-3814.
9. Zenz T, Mohr J, Edelmann J, et al. Treatment resistance in chroniclymphocytic leukemia: the role of the p53 pathway. Leuk Lymphoma 2009;50:510-513.
10. Zenz T, Frohling S, Mertens D, et al. Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL). Best PractRes Clin Haematol 2010;23:71-84.
11. S turm I, Bosanquet AG, Hermann S, et al. Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequenceof prior DNA-damaging chemotherapy. Cell Death Differ 2003;10: 477-484.
12. S tilgenbauer S, Sander S, Bullinger L, et al. Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomicaberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica 2007;92:1242-1245.
13. Stilgenbauer S, Zenz T. Understanding and managing ultra highrisk chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2010;2010:481-488.
14. Z enz T, Mertens D, Kuppers R, et al. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010;10: 37-50.
15. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446-5456.
16. G ryshchenko I, Hofbauer S, Stoecher M, et al. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia. J Clin Oncol 2008;26:2252-2257.
17. Z enz T, Habe S, Denzel T, et al. Detailed analysis of p53 pathway defects in fl udarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 2009;114:2589-2597.
18. Z enz T, Mohr J, Eldering E, et al. miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood 2009;113:3801-3808.
19. D urocher D, Jackson SP. DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme? Curr Opin Cell Biol 2001;13:225-231.
20. S hiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 2003;3:155-168.
21. K ruse JP, Gu W. Modes of p53 regulation. Cell 2009;137:609-622.
22. W ang Z, Li B. Mdm2 links genotoxic stress and metabolism top53. Protein Cell 2010;1:1063-1072.
23. B ommer GT, Gerin I, Feng Y, et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 2007;17: 1298-1307.
24. R iley T, Sontag E, Chen P, et al. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008;9:402-412.
25. B eckerman R, Prives C. Transcriptional regulation by p53. Cold Spring Harb Perspect Biol 2010;2:a000935.
26. F eng Z, Zhang C, Wu R, et al. Tumor suppressor p53 meets microRNAs. J Mol Cell Biol 2011;3:44-50.
27. L iang Y, Lin SY, Brunicardi FC, et al. DNA damage response pathways in tumor suppression and cancer treatment. World J Surg 2009;33:661-666.
28. M eek DW. Tumour suppression by p53: a role for the DNA damage response? Nat Rev Cancer 2009;9:714-723.
29. O zaki T, Nakagawara A. p53: the attractive tumor suppressor in the cancer research field. J Biomed Biotechnol 2011;2011:603925.
30. W attel E, Preudhomme C, Hecquet B, et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994;84:3148-3157.
31. D ohner H, Fischer K, Bentz M, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995;85:1580-1589.
32. D ohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-1916.
33. M alcikova J, Smardova J, Rocnova L, et al. Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage. Blood 2009;114:5307-5314.
34. Z enz T, Mertens D, Dohner H, et al. Importance of genetics in chronic lymphocytic leukemia. Blood Rev 2011;25:131-137.
35. Z enz T, Krober A, Scherer K, et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 2008;112:3322-3329.
36. D icker F, Herholz H, Schnittger S, et al. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia 2009;23:117-124.
37. R ossi D, Cerri M, Deambrogi C, et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res 2009;15:995-1004.
38. Z enz T, Eichhorst B, Busch R, et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 2010;28:4473-4479.
39. G onzalez D, Martinez P, Wade R, et al. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol 2011;29:2223-2229.
40. S addler C, Ouillette P, Kujawski L, et al. Comprehensive biomarker and genomic analysis identifi es p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood 2008;111:1584-1593.
41. C atovsky D, Richards S, Matutes E, et al. Assessment of fl udarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007;370:230-239.
42. G rever MR, Lucas DM, Dewald GW, et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol 2007;25:799-804.
43. Turgut B, Vural O, Pala FS, et al. 17p deletion is associated with resistance of B-cell chronic lymphocytic leukemia cells to in vitro fl udarabine-induced apoptosis. Leuk Lymphoma 2007;48:311-320.
44. Trbusek M, Smardova J, Malcikova J, et al. Missense mutations located in structural p53 DNA-binding motifs are associated wiThextremely poor survival in chronic lymphocytic leukemia. J Clin Oncol 2011;29:2703-2708.
45. F egan C, Robinson H, Thompson P, et al. Karyotypic evolution in CLL: identification of a new sub-group of patients with deletions of 11q and advanced or progressive disease. Leukemia 1995;9:2003-2008.
46. Dohner H, Stilgenbauer S, James MR, et al. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood 1997;89:2516-2522.
47. Stankovic T, Stewart GS, Fegan C, et al. Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage. Blood 2002;99:300-309.
48. A usten B, Skowronska A, Baker C, et al. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol 2007;25:5448-5457.
49. A usten B, Powell JE, Alvi A, et al. Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. Blood 2005;106: 3175-3182.
50. Cejkova S, Rocnova L, Potesil D, et al. Presence of heterozygous ATM deletion may not be critical in the primary response of chronic lymphocytic leukemia cells to fl udarabine. Eur J Haematol 2009;82: 133-142.
51. T simberidou AM, Tam C, Abruzzo LV, et al. Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia. Cancer 2009;115:373-380.
52. Stilgenbauer S, Zenz T, Winkler D, et al. Subcutaneous alemtuzumab in fl udarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2009;27:3994-4001.
53. V alganon M, Giraldo P, Agirre X, et al. p53 aberrations do not predict individual response to fl udarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages Rai III/IV. Br J Haematol 2005;129:53-59.
54. K onikova E, Kusenda J. Altered expression of p53 and MDM2 proteins in hematological malignancies. Neoplasma 2003;50:31-40.
55. B aran-Marszak F, Feuillard J, Najjar I, et al. Differential roles of STAT1alpha and STAT1beta in fl udarabine-induced cell cycle arrest and apoptosis in human B cells. Blood 2004;104:2475-2483.
56. Romanov VV, James CH, Sherrington PD, et al. Basic fi broblast growth factor suppresses p53 activation in the neoplastic cells of a proportion of patients with chronic lymphocytic leukaemia. Oncogene 2005;24:6855-6860.
57. Willander K, Ungerback J, Karlsson K, et al. MDM2 SNP309 promoter polymorphism, an independent prognostic factor in chronic lymphocytic leukemia. Eur J Haematol 2010;85:251-256.
58. Asslaber D, Pinon JD, Seyfried I, et al. microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia. Blood 2010;115:4191-4197.
59. M erkel O, Asslaber D, Pinon JD, et al. Interdependent regulation of p53 and miR-34a in chronic lymphocytic leukemia. Cell Cycle 2010;9:2764-2768.
60. Chang TC, Wentzel EA, Kent OA, et al. Transactivation of miR-34a by p53 broadly infl uences gene expression and promotes apoptosis. Mol Cell 2007;26:745-752.
61. T arasov V, Jung P, Verdoodt B, et al. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 2007;6:1586-1593.
62. Y amakuchi M, Ferlito M, Lowenstein CJ. miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci USA 2008;105: 13421-13426.
63. Jones GG, Carter A, Pettitt AR, et al. The arginine-encoding variant of the p21 (CDKN1A, p21WAF, Cip1) codon 31 polymorphism is over-represented in patients with CLL and is associated with failure of p21 induction following irradiation. Leuk Lymphoma 2005;46 (Suppl. 1):S56.
64. J ohnson GG, Sherrington PD, Carter A, et al. A novel type of p53 pathway dysfunction in chronic lymphocytic leukemia resulting from two interacting single nucleotide polymorphisms within the p21 gene. Cancer Res 2009;69:5210-5217.
65. L ee JY, Yu SJ, Park YG, et al. Glycogen synthase kinase 3beta phosphorylates p21WAF1/CIP1 for proteasomal degradation after UV irradiation. Mol Cell Biol 2007;27:3187-3198.
66. B astin-Coyette L, Cardoen S, Smal C, et al. Nucleoside analogs induce proteasomal down-regulation of p21 in chronic lymphocytic leukemia cell lines. Biochem Pharmacol 2011;81:586-593.
67. S tarczynski J, Pepper C, Pratt G, et al. Common polymorphism G(-248)A in the promoter region of the bax gene results in significantly shorter survival in patients with chronic lymphocytic leukemia once treatment is initiated. J Clin Oncol 2005;23:1514-1521.
68. S yed N, Smith P, Sullivan A, et al. Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignancies. Blood 2006;107:250-256.
69. B uggins AG, Pepper CJ. The role of Bcl-2 family proteins in chronic lymphocytic leukaemia. Leuk Res 2010;34:837-842.
70. I liakis G, Wang Y, Guan J, et al. DNA damage checkpoint control in cells exposed to ionizing radiation. Oncogene 2003;22:5834-5847.
71. H eisig P. Type II topoisomerases-inhibitors, repair mechanisms and mutations. Mutagenesis 2009;24:465-469.
72. R astogi RP, Richa, Kumar A, et al. Molecular mechanisms of ultraviolet radiation-induced DNA damage and repair. J Nucleic Acids 2010;2010:592980.
73. V an den Neste E, Cardoen S, Off ner F, et al. Old and new insights into the mechanisms of action of two nucleoside analogs active in lymphoid malignancies: fl udarabine and cladribine (review). Int J Oncol 2005;27:1113-1124.
74. E wald B, Sampath D, Plunkett W. Nucleoside analogs: molecular mechanisms signaling cell death. Oncogene 2008;27:6522-6537.
75. R obak T, Korycka A, Lech-Maranda E, et al. Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases. Molecules 2009;14:1183-1226.
76. K ojima K, Konopleva M, McQueen T, et al. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atmmediated resistance to fl udarabine in chronic lymphocytic leukemia. Blood 2006;108:993-1000.
77. S ecchiero P, Barbarotto E, Tiribelli M, et al. Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood 2006;107:4122-4129.
78. Bixby D, Kujawski L, Wang S, et al. The pre-clinical development of MDM2 inhibitors in chronic lymphocytic leukemia uncovers a central role for p53 status in sensitivity to MDM2 inhibitor-mediated apoptosis. Cell Cycle 2008;7:971-979.
79. J ones GG, Reaper PM, Pettitt AR, et al. The ATR-p53 pathway is suppressed in noncycling normal and malignant lymphocytes. Oncogene 2004;23:1911-1921.
80. Le Garff-Tavernier M, Blons H, Nguyen-Khac F, et al. Functional assessment of p53 in chronic lymphocytic leukemia. Blood Cancer J 2011; 1.
81. C arter A, Lin K, Sherrington PD, et al. Detection of p53 dysfunction by fl ow cytometry in chronic lymphocytic leukaemia. Br J Haematol 2004;127:425-428.
82. C arter A, Lin K, Sherrington PD, et al. Imperfect correlation between p53 dysfunction and deletion of TP53 and ATM in chronic lymphocytic leukaemia. Leukemia 2006;20:737-740.
83. M ohr J, Helfrich H, Fuge M, et al. DNA damage-induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing. Blood 2011;117:1622-1632.
84. P ettitt AR, Sherrington PD, Stewart G, et al. p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Blood 2001;98:814-822.
85. M ackus WJ, Kater AP, Grummels A, et al. Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation. Leukemia 2005;19:427-434.
86. d e Viron E, Knoops L, Connerotte T, et al. Impaired up-regulation of polo-like kinase 2 in B-cell chronic lymphocytic leukaemia lymphocytes resistant to fl udarabine and 2-chlorodeoxyadenosine: a potential marker of defective damage response. Br J Haematol 2009;147:641-652.
87. Mous R, Jaspers A, Luijks DM, et al. Detection of p53 dysfunction in chronic lymphocytic leukaemia cells through multiplex quantification of p53 target gene induction. Leukemia 2009;23:1352-1355.
88. Stankovic T, Hubank M, Cronin D, et al. Microarray analysis reveals that TP53-and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses. Blood 2004; 103:291-300.
89. Dijkstra MK, van Lom K, Tielemans D, et al. 17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation. Leukemia 2009;23:625-627.
90. Mraz M, Malinova K, Kotaskova J, et al. miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities. Leukemia 2009;23:1159-1163.
91. R ossi S, Shimizu M, Barbarotto E, et al. microRNA fi ngerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifi es early survival. Blood 2010;116:945-952.
92. di Iasio MG, Addobbati R, Radillo O, et al. Nutlin-3 differentially modulates miRNA34a and miRNA181 versus miR26a and miR155 in p53 proficient and p53 deficient B chronic lymphocytic leukemia (B-CLL) samples. Invest New Drugs 2011 May 31. [Epub ahead of print]
93. Best OG, Gardiner AC, Majid A, et al. A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL. Leukemia 2008;22:1456-1459.
94. Best OG, Gardiner AC, Davis ZA, et al. A subset of Binet stage-Rfaut CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease. Leukemia 2009;23:212-214.
95. Pettitt AR, Carter A, Lenehan K, et al. Functional impairment of the p53 pathway detected by fl ow cytometry is a novel independent adverse prognostic factor in chronic lymphocytic leukaemia. Haematologica 2007;92(Suppl. 2): Abstract 0910.
96. Zenz T, Habe S, Denzel T, et al. How little is too much? p53 inactivation: from laboratory cutoff to biological basis of chemotherapy resistance. Leukemia 2008;22:2257-2258.
97. Lin K, Sherrington PD, Dennis M, et al. Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia. Blood 2002;100:1404-1409.
98. V ogelstein B, Lane D, Levine AJ. Surfi ng the p53 network. Nature 2000;408:307-310.
99. Lin K, Carter A, Rockliff e N, et al. Functional impairment of the p53 pathway detected by fl ow cytometry is an independent predictor of early progression and short survival in chronic lymphocytic leukaemia (CLL). Paper presented at NCRI Cancer Conference. 7-10 November 2010. BT Convention Center, Liverpool, UK.
100. Pettitt AR, Sherrington PD, Cawley JC. The eff ect of p53 dysfunction on purine analogue cytotoxicity in chronic lymphocytic leukaemia. Br J Haematol 1999;106:1049-1051.
101. L in K, Manocha S, Harris RJ, et al. High frequency of p53 dysfunction and low level of VH mutation in chronic lymphocytic leukemia patients using the VH3-21 gene segment. Blood 2003;102:1145-1146.
102. Willmore E, Elliott SL, Mainou-Fowler T, et al. DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia. Clin Cancer Res 2008;14: 3984-3992.
103. S ampath D, Calin GA, Puduvalli VK, et al. Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation. Blood 2009;113:3744-3753.